article thumbnail

FDA clears Intellia to start US tests of ‘in vivo’ gene editing drug

Bio Pharma Dive

The announcement, which follows recent regulatory setbacks for some of Intellia’s peers, is a “big win” for the gene editing field, according to one analyst

article thumbnail

Moderna inks another gene editing deal

Bio Pharma Dive

The messenger RNA specialist said Wednesday it is teaming up with Life Edit Therapeutics to develop therapies that can modify genes “in vivo

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA sets out advice to developers of gene editing medicines

Bio Pharma Dive

Draft recommendations from the agency were generally straightforward, analysts said, although the document emphasized the potential safety risks of gene editing

article thumbnail

AstraZeneca to acquire gene editing biotech LogicBio

Bio Pharma Dive

Shares in LogicBio had lost nearly all their value since a 2018 IPO, bringing the company to the brink of Nasdaq delisting. The buyout deal represents a premium of over 600

article thumbnail

Pfizer expands into gene editing with Beam research deal

Bio Pharma Dive

Pfizer's work with mRNA vaccines led it explore other applications of the technology, resulting in a multi-year partnership with the high-profile biotech Beam Therapeutics on gene editing treatments for rare diseases

article thumbnail

Vertex, Verve team up to develop a gene editing drug for liver disease

Bio Pharma Dive

The deal, which is worth $60 million upfront, broadens Vertex’s reach into gene editing and expands Verve’s research beyond heart disease

article thumbnail

Vertex aligns with another CRISPR gene editing startup

Bio Pharma Dive

A new alliance with Mammoth Biosciences marks the latest evidence of Vertex's interest in gene editing, which has already been the focus of multiple deals with emerging biotechs

article thumbnail

Beam, Apellis partner in deal to expand gene editing's reach

Bio Pharma Dive

The companies aim to develop therapies for complement-driven diseases, a specialty of Apellis and relatively new research ground for gene editing

article thumbnail

Moderna, teaming with a startup, wades further into gene editing

Bio Pharma Dive

The biotech has identified gene editing as a natural fit for the technology it uses to deliver its vaccines and drugs. A deal with Metagenomi, a startup backed by Bayer, will further those ambitions

article thumbnail

Gene editing biotech Verve to raise $267M in large IPO

Bio Pharma Dive

Capitalizing on investor interest in gene editing, the high-profile startup has secured one of the richest biotech initial public offerings priced this year

article thumbnail

Gene editing: beyond the hype

Pharma Phorum

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Zinc fingers are the most common control gene in the body,” Macrae explains. “We Gene therapy can ultimately only take you into the liver,” he explains.

article thumbnail

Sarepta reveals gene editing alliance with biotech exploring alternative delivery methods

Bio Pharma Dive

The collaboration with GenEdit, a South San Francisco startup developing new ways of delivering gene editing tools into the body, dates back to December 2020, but has recently begun to advance

article thumbnail

Gene editing startup iECURE returns to investors for fresh funding

Bio Pharma Dive

The company, which draws on research by Jim Wilson’s lab at UPenn, says the $65 million it raised will support the start of human testing of its lead drug through to initial clinical data

article thumbnail

Intellia, with first results, delivers a 'landmark' for CRISPR gene editing

Bio Pharma Dive

Results published in The New England Journal of Medicine offer the first clinical evidence that CRISPR gene editing inside the body can be safe and effective, a culmination of years of scientific research

article thumbnail

Caribou raises $304M in one of gene editing's most lucrative IPOs

Bio Pharma Dive

The IPO is several times larger than what CRISPR Therapeutics, Intellia and Editas raised several years ago, and ranks well ahead of a more recent offering from gene editing startup Beam

article thumbnail

Lilly dives into gene editing

Bio Pharma Dive

Through a deal with Precision Biosciences, the pharma aims to develop therapies for genetic disorders, including Duchenne muscular dystrophy

article thumbnail

Vertex, CRISPR strengthen case for pioneering gene-editing treatment

Bio Pharma Dive

Positive data from 75 patients with either sickle cell disease or beta thalassemia keep the companies’ therapy on track to become the first CRISPR-based treatment submitted to drug regulators, possibly by the end of the year

article thumbnail

Gene editing biotechs face new uncertainty after CRISPR patent ruling

Bio Pharma Dive

A federal patent board ruled Broad Institute scientists were first to a key gene editing advance, weakening the patent position of Intellia and CRISPR Therapeutics, which hold licenses through the University of California

article thumbnail

FDA halts Verve plans to test gene editing therapy for heart disease in US

Bio Pharma Dive

Verve didn’t say what led to the FDA’s decision, but claimed it hasn’t observed any safety issues in an ongoing trial in New Zealand and the U.K, where enrollment will continue

article thumbnail

Moderna's Latest Partnership Combines mRNA with Gene Editing

BioSpace

Moderna's Latest Partnership Combines mRNA with Gene Editing 2/22/2023

article thumbnail

Gene editing startup Metagenomi raises $175M to advance research pipeline

Bio Pharma Dive

The biotech raised the Series B round during "probably one of the worst biotech markets" emerging drugmakers have faced in some time, a Metagenomi executive told BioPharma Dive

article thumbnail

Moderna partners with Life Edit for mRNA gene editing therapies

Pharmaceutical Technology

Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. Life Edit will get an upfront payment and is eligible for potential milestone payments.

article thumbnail

AbbVie exploring how CRISPR gene editing can improve cell therapies

Bio Pharma Dive

Using technology from Caribou Biosciences, AbbVie hopes to engineer "off-the-shelf" CAR-T cells that can better withstand attacks from the immune system

article thumbnail

Vertex, CRISPR prep filing for gene-editing blood disorder therapy

Pharma Phorum

Vertex Pharma and partner CRISPR Therapeutics will start a rolling marketing application in the US for their gene-editing drug for sickle cell disease (SCD) and beta thalassaemia later this year.

article thumbnail

Asklepios partners with ReCode on gene-editing platform

Pharmaceutical Technology

Asklepios BioPharmaceutical has entered a research partnership and option agreement with ReCode Therapeutics for exploring its single-vector gene-editing platform. Asklepios expects that the partnership can extend the gene editing reach for lung and liver disease targets.

article thumbnail

Ionis teams with Metagenomi and dives into gene editing

Bio Pharma Dive

The RNA drug developer is paying the richly-funded startup $80 million in a wide-ranging alliance that marks its first foray into DNA editing medicines

article thumbnail

New CRISPR-Based Tool Called PASTE Gene Editing Inserts Large DNA Sequences at Desired Sites

XTalks

Expanding upon the CRISPR-Cas9 gene editing system, researchers at MIT have designed a new technique called PASTE gene editing that can cut out defective genes and replace them with new genes in a safer and more efficient way.

article thumbnail

After long wait, Editas reveals first data for CRISPR gene editing treatment

Bio Pharma Dive

Early study results offer some hopeful signs of efficacy, but the small number of patients treated and short follow-up limit firmer conclusions

article thumbnail

Verve starts first human test of gene editing treatment for heart disease

Bio Pharma Dive

A patient in New Zealand became the first person to receive the biotech’s medicine, which uses base editing to turn off a specific gene in the liver and thereby lower cholesterol

article thumbnail

EHA: Vertex, CRISPR build case for gene-editing drug

Pharma Phorum

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical trial, with an update at the EHA congress showing long-term effects on the symptoms of both beta thalassaemia and sickle cell disease.

article thumbnail

Sanofi partners with Scribe to gain gene editing tools for cell therapy work

Bio Pharma Dive

The California biotech will receive $25 million upfront from Sanofi, which plans to use Scribe’s platform to edit natural killer cells for cancer treatment

article thumbnail

Prime Medicine raises $315M to fuel 'search-and-replace' gene editing work

Bio Pharma Dive

Formed around research from the Broad Institute's David Liu and Andrew Anzalone, Prime has attracted significant funding from a wide range of high-profile biotech backers

article thumbnail

A CRISPR gene editing treatment continues to show promise for two blood diseases

Bio Pharma Dive

Results from 10 patients with beta thalassemia or sickle cell disease show CRISPR Therapeutics and Vertex's pioneering treatment to be effective, building on earlier study data

article thumbnail

JPM21: Gene editing for heart disease, a new date to watch in Alzheimer's and Pfizer's deep pockets

Bio Pharma Dive

Verve, a buzzy gene editing startup, unveiled its first drug candidate on Tuesday, while Eli Lilly's and Pfizer's CEO gave updates on Alzheimer's and dealmaking

article thumbnail

Editas, AbbVie rework gene editing deal as pioneering CRISPR trial resumes

Bio Pharma Dive

Development of EDIT-101, the first CRISPR-based therapy to be used in a company-led trial to alter genes within a person's body, will now move forward under Editas' sole ownership

article thumbnail

CRISPR, with new partner, to develop gene editing therapies for ALS, nerve disorder

Bio Pharma Dive

A deal with biotech startup Capsida, which recently raised $140 million, gives CRISPR access to a Caltech technology that aims to improve the delivery of genetic medicines

article thumbnail

Vertex, looking to broaden its gene editing abilities, asks a young biotech for help

Bio Pharma Dive

A freshly inked agreement gives Vertex the right to use tools from Arbor Biotechnology to develop "ex vivo" cell therapies for diseases like Type 1 diabetes and sickle cell, among others

article thumbnail

Gene-Editing the Microbiome: The Limitless Possibilities

BioSpace

Eligo Bioscience has thought of a way to solve the dysbiosis between our bodies and our microbiomes – gene editing. BioSpace spoke with Eligo Co-founder and CEOXavier Duportet, Ph.D.

article thumbnail

Doudna-founded biotech Caribou raises fresh funds to fuel gene editing pipeline

Bio Pharma Dive

The CRISPR biotech raised $115 million in a Series C financing aimed at advancing its engineered cell therapy research

article thumbnail

Pushing Beyond Gene Editing Limits with Programmable RNA Medicines

BioSpace

Shape Therapeutics is evolving programmable RNA medicines that push the limits of current gene editing capabilities. BioSpace spoke with CSO David Huss

article thumbnail

Bayer and Mammoth Biosciences collaborate on novel gene editing tech

BioPharma Reporter

have announced a strategic collaboration and option agreement for the use of Mammothâs CRISPR systems to develop in vivo gene-editing therapies. Bayer AG and Mammoth Biosciences, Inc.,

article thumbnail

Will Intellia Make Gene Editing History Saturday?

BioSpace

In what will be a big moment for CRISPR technology, Intellia and development partner, Regeneron Pharmaceuticals will share the world’s first data from a therapy that edits flawed genes inside the body

article thumbnail

Gene-editing used to create single sex mice litters

Scienmag